Fortis Hospital Mohali (FHM) has been Internationally Accredited by Joint Commission International (JCI) since 2007(renewed for the 6th consecutive time in 2022). It is also the proud recipient of accreditation from National Accreditation Board of Hospitals (NABH), India (renewed for the 4th time in 2017). These accreditations ensure that the highest and strictest patient safety standards are followed in the hospital. It is the veritable torch bearer of super specialty centers of excellence across the country. With 348 beds, this tertiary care hospital has established itself as one of the best cardiac care centers in the region.
Established in 2001, Fortis Hospital Mohali has successfully managed to develop world class facilities. Fortis Hospital Mohali is a pioneer in high end procedures like Transcatheter Aortic Valve Implantation (TAVI), Left Ventricular Assist Device (LVAD), Right Ventricular Assist Device (RVAD), Minimally Invasive Direct Coronary Artery Bypass Surgery (MIDCAB), Breast Conservation with immediate and delayed Reconstruction for Breast Cancer, Sentinel Lymph Node Biopsy, Robot Assisted Surgery, Interventional Neuroradiology, Interventional Gastroenterology, Paediatric Arterial Switch Operation, Aortic Aneurysms, Tumour Surgery, and Radical Dissection for Oesophageal Cancer and Comprehensive Cancer Treatment Facility.
Fortis Cancer Institute (FCI), inaugurated in 2014, is the region’s most modern Comprehensive Cancer Care Centre offering Medical, Surgical & Radiation Oncology. The Cancer Treatment Programme at FCI ensures that every patient is reviewed by a Tumour Board consisting of Medical, Surgical and Radiation Oncologists. It has the region’s most advanced Linear Accelerator with VMAT. Coupled with IGRT, SRS, SRT & ART the treatment ensures that only the cancer cells are destroyed, and the surrounding healthy tissue are spared. This ensures minimal burns, side-effects & shorter treatment span. Treatment is delivered with sub-mm accuracy. In addition, FCI has Conventional, 3D and IMRT modalities, along with Siemens Biograph Truepoint with HD PET-CT. It combines the benefits of both PET and CT. It has the ability to detect lesions as small as I mm, with minimal radio pharmaceutical dose. FHM also offers DCT (Dendritic Cell Therapy), wherein the dendritic cells help the immune system recognize and attack abnormal cells, including cancer cells.